you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes

October 2012

New generics plus bladder cancer concerns mean you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes.

Actos is one of the top 25 prescribed drugs in the U.S...and lower prices for the generic could tempt more prescribers to use it.

But some providers are reluctant to use it due to growing concerns about bladder cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Infectious Diseases This will be the worst year yet for West Nile virus
Overactive Bladder Myrbetriq (meer-BEH-trick, mirabegron) for overactive bladder
Diabetes you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes
Hypertension debate about when to start drugs in patients with MILD hypertension
Vaccines New virus strains in the 2012-2013 influenza vaccine
Antipsychotics whether it makes sense to use more than one antipsychotic for schizophrenia
STIs Oral cefixime is no longer first-line for gonorrhea
Depression more emphasis on treating depression in cardiac patients
Respiratory & Allergy The new OTC bronchodilator Asthmanefrin (racepinephrine) will be promoted as an alternative to Primatene Mist (epinephrine)
Respiratory & Allergy whether inhaled corticosteroids inhibit growth in kids or increase fracture risk in seniors
Substance Use Disorder Patients are abusing Suboxone (buprenorphine/naloxone) tabs
Education and Training how and why you need to get an e-Profile ID to meet the new CE reporting requirements